Today@ADA | DAY 1

Welcome to Today@ADA – a round-up of our picks from the day’s program at the 81st Scientific Sessions of the American Diabetes Association. You can revisit anything you missed and want to catch-up with in full in the on-demand sessions.

Today, my interview is with Alan Remaley from the National Institutes of Health in Bethesda, who presented on the potential role of lipids and lipid therapies in modulating COVID-19 infections.

In my overview for today, the first pick is from John Buse – from the University of North Carolina School of Medicine. In his presentation he gave us an overview of how the joint ADA/EASD and KDIGO guidelines for diabetes and chronic kidney disease compare. He showed the key areas, and highlighted where the specialist KDIGO guidelines offer more detail. I have echoed a few topline details around the goals of care, and the need for comprehensive management in these patients. That is followed by Quinn Peterson discussing the progress that has been made in stem cell-derived islets, looking at multiple therapies in development across cell types in the quest to create a designer islet. Finally, my last pick for today is focused on the influence of time-restricted feeding. In this presentation, Courtney Peterson from the University of Alabama at Birmingham showcases clinical trial results, and offers some practical considerations. I have selected highlights from her presentation to give an overview of what time-restricted eating is, and the benefits it can offer – including improvements in cardiometabolic health.  

I hope you enjoy this overview. We will be back with more for Day 2. 


Dr. Dana Dabelea

ADA Highlights 2021 Editor
Denver, CO, USA

About ADA Feedback Post Test